Email: cspc@cspc.cn
News
January 09, 2023
Share:
Previous: Octreotide Long-Acting Injection Obtains Clinical Trial Approval
Next: Meloxicam Nanocrystal Injection Obtains Clinical Trial Approval
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us